Cellectar Biosciences, Inc. (CLRB)
| Market Cap | 11.67M -8.8% |
| Revenue (ttm) | n/a |
| Net Income | -22.32M |
| EPS | -3.75 |
| Shares Out | 9.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,335 |
| Open | 1.220 |
| Previous Close | 1.240 |
| Day's Range | 1.215 - 1.248 |
| 52-Week Range | 1.120 - 4.700 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+831.17%) |
| Est. Earnings | Nov 12, 2026 |
About CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 cli... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CLRB stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 831.17% from the latest price.
News
Cellectar’s iopofosine case study shows complete response over 8 years
Cellectar Biosciences (CLRB) announced results from a case study highlighting a durable complete response in a heavily pretreated patient with diffuse large B-cell lymphoma treated with iopofosine I 1...
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential...
Cellectar Biosciences presents efficacy data from CLOVER WaM trial
Cellectar Biosciences (CLRB) announced that efficacy results from a subset of patients treated with iopofosine I 131 immediately post-Bruton Tyrosine Kinase inhibitor, or BTKi, therapy in the company’...
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 mont...
Cellectar Biosciences Slides: Corporate presentation
Cellectar Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on October 2, 2026.
Cellectar Biosciences to present data from Phase 2 CLOVER WaM trial
Cellectar Biosciences (CLRB) announced that a subset analysis of data from the company’s Phase 2 CLOVER WaM clinical trial that support the potential of iopofosine I 131 as a potential…
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BT...
Cellectar Biosciences Transcript: Study update
A phospholipid ether platform enables antigen-independent, selective delivery of diverse therapeutic payloads to a wide range of cancers by targeting lipid rafts. Clinical and preclinical data show strong efficacy and tumor selectivity, with ongoing expansion into new modalities and tumor types.
Cellectar Biosciences Slides: Study update
Cellectar Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Cellectar Biosciences Slides: Corporate presentation
Cellectar Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)
“Our second quarter marked another period of significant execution as we continued to advance multiple programs across our oncology pipeline while laying the foundation for several important near-term...
Cellectar Biosciences Earnings Call Transcript: Q2 2026
Q2 2026 saw strong clinical and regulatory progress, highlighted by positive iopofosine data in WM, initiation of a phase III trial, and strengthened finances via a $140M financing. The company is on track for an Accelerated Approval submission in 2027 and expanding its radiopharmaceutical pipeline.
Cellectar Biosciences Quarterly report: Q2 2026
Cellectar Biosciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
Cellectar Biosciences Earnings release: Q2 2026
Cellectar Biosciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for ...
Cellectar Biosciences Slides: Corporate presentation
Cellectar Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2026.
Cellectar Biosciences publishes iopofosine I 131 dose-escalation study results
Cellectar Biosciences (CLRB) announced the publication of results from a Phase 1 dose-escalation study evaluating iopofosine I 131 in combination with low-dose dexamethasone in 31 patients with heavil...
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma
Cellectar Biosciences initiated with a Buy at Brookline
Brookline initiated coverage of Cellectar Biosciences (CLRB) with a Buy rating and $15 price target
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy
Cellectar Biosciences Slides: Corporate presentation
Cellectar Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Cellectar Biosciences Registration statement: Registration filing
Cellectar Biosciences filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.
Cellectar Biosciences Proxy statement: Proxy filing
Cellectar Biosciences filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Cellectar Biosciences Proxy statement: Proxy filing
Cellectar Biosciences filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.